No Data
No Data
Jilin Province Xidian Pharmaceutical Sci-Tech DevelopmentLtd's (SZSE:301130) Problems Go Beyond Weak Profit
Westpoint Pharmaceuticals (301130.SZ): has cumulatively repurchased 4.995% of shares.
On September 2nd, Golonghui announced that as of August 30th, 2024, the company has repurchased 4,036,458 shares of the company's stock through a repurchase special securities account through centralized bidding trading, accounting for 4.9953% of the company's current total share capital. The highest fill price was 26.22 yuan per share, and the lowest fill price was 20.65 yuan per share, with a total fill amount of 93.4189 million yuan (excluding transaction fees).
West Point Pharmaceuticals: Semi-Annual Report 2024
West Point Pharmaceuticals: 2024 Semi-Annual Report Summary
Westpoint Pharmaceuticals (301130.SZ): The net income for the first half of the year was 24.4517 million yuan, a year-on-year decrease of 19.36%.
On August 28th, Sino Point Pharmaceuticals (301130.SZ) released its semi-annual report for 2024. During the reporting period, the revenue was 0.129 billion yuan, with a year-on-year growth of 13.04%. The net income attributable to shareholders of the listed company was 24.4517 million yuan, with a year-on-year decrease of 19.36%. The net income attributable to shareholders of the listed company after deducting non-recurring gains and losses was 20.8314 million yuan, with a year-on-year increase of 39.10%. The basic earnings per share were 0.3026 yuan.
Xide Pharmaceutical (301130.SZ): Approved products and products under registration that are being researched do not include monkeypox treatment drugs such as Tekovir.
On August 21, Gralon Pharmaceuticals (301130.SZ) stated on the investor interaction platform that the company's approved products and research products in the registration process do not include monkeypox treatment drugs such as Tocilizumab.
No Data
No Data